AAA
OLMA icon

Affinity Asset Advisors’s Olema Pharmaceuticals OLMA Stock Holding History

Affinity Asset Advisors’s Portfolio OLMA Stock Details OLMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-250,000
Closed -$2.45M – 113
2025
Q3 		$2.45M Buy
+250,000
New +$1.5M 0.21% 70

Other funds holding OLMA

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Affinity Asset Advisors's OLMA Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Olema Pharmaceuticals (OLMA) in Q4 2025, closing a stake of 250,000 shares — an estimated $2.45M sold.

Affinity Asset Advisors first reported a position in OLMA in Q2 2024 and held it in 4 quarters. The position peaked at $2.98M in Q2 2024. 200 funds tracked by Wall St. Rank hold OLMA as of Q4 2025.

  • Affinity Asset Advisors reported no remaining Olema Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Affinity Asset Advisors sold 250,000 Olema Pharmaceuticals shares in Q4 2025, an estimated $2.45M.
  • Affinity Asset Advisors first reported a position in Olema Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Affinity Asset Advisors's Olema Pharmaceuticals position peaked at $2.98M in Q2 2024.
  • 200 funds tracked by Wall St. Rank held Olema Pharmaceuticals as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.